Ivabradine as an Adjuvant Agent for Severe Heart Failure Occurring in the Early Phase after Allogeneic Hematopoietic Cell Transplantation |
| |
| Authors: | Ryo Yanagiya Masahiro Wanezaki Naohisa Nakamura Tsubasa Ichikawa Tatsuya Hayasaka Akane Yamada Keiko Aizawa Satoshi Ito Masahito Himuro Hiroto Suzuki Masakazu Yamamoto Tomomi Toubai Masafumi Watanabe Kenichi Ishizawa |
| |
| Affiliation: | 1.Department of Neurology, Hematology, Metabolism, Endocrinology and Diabetology (3rd Department of Internal Medicine), Faculty of Medicine, Yamagata University, Japan; 2.1st Department of Internal Medicine, Faculty of Medicine, Yamagata University, Japan; 3.Department of Critical Care Unit, Yamagata University Hospital, Japan |
| |
| Abstract: | Cardiotoxicity is a critical complication of allogeneic hematopoietic cell transplantation (allo-HCT). In particular, management of severe cardiotoxicity occurring in the early phases of allo-HCT is challenging. We encountered a case of severe cardiotoxicity resulting from AHF six days after allo-HCT, which resisted catecholamines and diuretics. The patient was treated with anthracycline-containing regimens and underwent myeloablative conditioning, including high-dose cyclophosphamide. As invasive circulatory assisting devices were contraindicated because of his immunocompromised status and bleeding tendency, we successfully treated the patient with ivabradine-containing medications. Ivabradine may therefore be considered an alternative drug for the treatment of severe cardiotoxicity induced by cytotoxic agents. |
| |
| Keywords: | ivabradine cardiotoxicity acute heart failure allogeneic hematopoietic cell transplantation |
|
|
